Crossmark

A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer

Crossref DOI link: https://doi.org/10.1186/s40780-022-00261-y

Published Online: 2022-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Machida, Maiko http://orcid.org/0000-0002-3610-8916
Yamazaki, Chika

Kouda, Nao

Hanai, Yousei

Sato, Hideki

Konda, Ainari

Yamagata, Yuka

Itho, Tatsuya

Aisaka, Haruhiko
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (21K06648)
License Information

Text and Data Mining valid from 2022-12-05

Version of Record valid from 2022-12-05
More Information

Article History

Received: 24 August 2022

Accepted: 11 October 2022

First Online: 5 December 2022

Declarations

:

: This study (Research for early detection of adverse events of immune checkpoint inhibitors, UMIN000044022, registered 23 April 2021, ExternalRef removed) was approved by the Ethics Committee of Hokkaido University of Science and Japan Community Health Care Organization Sapporo Hokushin Hospital. Informed consent was obtained from the patient.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below